Invention Grant
- Patent Title: Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
-
Application No.: US15764495Application Date: 2016-08-19
-
Publication No.: US11021690B2Publication Date: 2021-06-01
- Inventor: Yun Jiang , Linqiu Huang , Jueren Lou
- Applicant: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
- Applicant Address: CN Shanghai
- Assignee: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
- Current Assignee: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
- Current Assignee Address: CN Shanghai
- Agency: Michael Best & Friedrich LLP
- Priority: CN201510638339.9 20150929
- International Application: PCT/CN2016/096094 WO 20160819
- International Announcement: WO2017/054590 WO 20170406
- Main IPC: C12N9/06
- IPC: C12N9/06 ; A61K47/60 ; C12Q1/62 ; A61K38/00
Abstract:
A mutant-type uricase, PEG modified mutant-type uricase, and application thereof. The mutant-type uricase has a cysteine residue introduced by recombination, the cysteine residue is located at an inactive region of the uricase, and one or more PEGs are coupled to the mutant-type uricase. The resulting PEGylated mutant-type uricase has characteristics of a half-life extension, product uniformity, and stable enzyme activity. Therefore, the present invention has a wide future application range.
Public/Granted literature
- US20180282707A1 MUTANT-TYPE URICASE, PEG MODIFIED MUTANT-TYPE URICASE, AND APPLICATION THEREOF Public/Granted day:2018-10-04
Information query
